Liraglutide
First-gen GLP-1 drug (Saxenda/Victoza). Less potent than semaglutide but has years of clinical data and established safety profile. Requires daily injection.
Key Facts
- ClassificationPeptide — First-gen GLP-1 drug (Saxenda/Victoza). Effective but weaker than semaglutide.
- Primary BenefitsFat Loss (8/10) · Longevity (4/10) · Gut Health (3/10)
- AdministrationInjection
- Typical DoseStart at 0.6 mg per day and gradually increase to 3.0 mg per day over several weeks. Daily injection required (shorter-lasting than semaglutide).
- Evidence StrengthStrong — 20 peer-reviewed studies referenced · Community sentiment 8/10
- Stacks Well With5-Amino-1MQ, BPC-157, MOTS-c
- Legal StatusFDA-Approved · prescription required · WADA prohibited
Quick Facts
- From price
- N/A
- Type
- peptide
- Administration
- Injection
- Evidence
- strong
- Studies referenced
- 20
- Community sentiment
- 8/10
- Stacks with
- 3 peptides
- Regulatory
- FDA-Approved
Top benefits
Dosing
Start at 0.6 mg per day and gradually increase to 3.0 mg per day over several weeks. Daily injection required (shorter-lasting than semaglutide).
Benefit Profile
| Vendor | Variant | Price | |
|---|---|---|---|
| Peptide Sciences ✕ Announced voluntary shutdown — stock availability may be limited or unavailable. Pricing data may be outdated. | 3mg | $79.00 | Out of stock |
Stacks Well With
5-Amino-1MQ
Small molecule blocking NNMT, an enzyme that slows metabolism. Increases NAD+ production and energy expenditure. Promotes fat loss and may fix metabolic issues.
BPC-157
A healing compound from human gastric juice. The most extensively studied repair peptide in animal models, with strong preclinical data for tissue repair, gut restoration, and anti-inflammatory effects. Human clinical data remains limited.
MOTS-c
Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.
Related 🔥 Fat Loss Peptides
Other peptides strong in fat loss
GLP-1 drug (Ozempic/Wegovy) that suppresses appetite and burns fat.
Tirzepatide10/10Dual GLP-1/GIP drug (Mounjaro/Zepbound). Strongest weight loss peptide available.
Retatrutide10/10Triple-action weight loss drug hitting GLP-1, GIP, and glucagon receptors.
CagriSema10/10Next-gen dual semaglutide + amylin analog with strongest weight loss data.
Survodutide9/10Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
Mazdutide9/10Dual GLP-1/glucagon receptor drug with strong weight loss results.